These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 9747820)

  • 21. Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian Phase II study.
    Demols A; Peeters M; Polus M; Honoré P; Boterberg T; Gay F; Closon MT; Van Houtte P; Closset J; Van Laethem JL
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1351-6. PubMed ID: 16029792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
    Regine WF; Winter KA; Abrams RA; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Kudrimoti MR; Fromm ML; Haddock MG; Schaefer P; Willett CG; Rich TA
    JAMA; 2008 Mar; 299(9):1019-26. PubMed ID: 18319412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer.
    McGinn CJ; Lawrence TS; Zalupski MM
    Cancer; 2002 Aug; 95(4 Suppl):933-40. PubMed ID: 12209674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current and emerging treatments for pancreatic cancer.
    Regine WF; John WJ; Mohiuddin M
    Drugs Aging; 1997 Oct; 11(4):285-95. PubMed ID: 9342558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
    Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB
    Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of different treatment methods on survival in advanced pancreatic cancer.
    Brasiūniene B; Juozaityte E; Barauskas G
    Medicina (Kaunas); 2005; 41(5):382-5. PubMed ID: 15947521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience.
    Rakhra S; Strauss JB; Robertson J; McGinn CJ; Kim T; Huang J; Blake A; Helenowski I; Hayes JP; Mulcahy M; Small W
    J Gastrointest Cancer; 2016 Jun; 47(2):196-201. PubMed ID: 27112332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant therapy for pancreatic adenocarcinoma: what have we learned since 1985?
    Abrams RA
    Int J Radiat Oncol Biol Phys; 2003; 56(4 Suppl):3-9. PubMed ID: 12826245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    Nukui Y; Picozzi VJ; Traverso LW
    Am J Surg; 2000 May; 179(5):367-71. PubMed ID: 10930481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival outcomes in patients with early stage, resected pancreatic cancer - a comparison of gemcitabine- and 5-fluorouracil-based chemotherapy and chemoradiation regimens.
    Kizilbash SH; Ward KC; Liang JJ; Jaiyesimi I; Lipscomb J
    Int J Clin Pract; 2014 May; 68(5):578-89. PubMed ID: 24472057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer.
    Joensuu TK; Kiviluoto T; Kärkkäinen P; Vento P; Kivisaari L; Tenhunen M; Westberg R; Elomaa I
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):444-52. PubMed ID: 15380578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiation therapy with once-weekly gemcitabine in pancreatic cancer: current status of clinical trials.
    McGinn CJ; Zalupski MM
    Int J Radiat Oncol Biol Phys; 2003; 56(4 Suppl):10-5. PubMed ID: 12826246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Radiation therapy in pancreatic cancer].
    Chie EK
    Korean J Gastroenterol; 2008 Feb; 51(2):101-10. PubMed ID: 18349572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
    McAllister F; Pineda DM; Jimbo M; Lal S; Burkhart RA; Moughan J; Winter KA; Abdelmohsen K; Gorospe M; Acosta Ade J; Lankapalli RH; Winter JM; Yeo CJ; Witkiewicz AK; Iacobuzio-Donahue CA; Laheru D; Brody JR
    Cancer Biol Ther; 2014 Jun; 15(6):688-98. PubMed ID: 24618665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
    Ben-Josef E; Shields AF; Vaishampayan U; Vaitkevicius V; El-Rayes BF; McDermott P; Burmeister J; Bossenberger T; Philip PA
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):454-9. PubMed ID: 15145162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
    Park JK; Ryu JK; Lee JK; Yoon WJ; Lee SH; Kim YT; Yoon YB
    Pancreas; 2006 Nov; 33(4):397-402. PubMed ID: 17079946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Chemoradiation for pancreatic adenocarcinoma].
    Flandin I; Mornex F; Claude L; Kubas A; Khodri M; Wautot V; Mazeron R; Partensky C
    Cancer Radiother; 2004 Nov; 8 Suppl 1():S80-7. PubMed ID: 15679252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pancreatic cancer: the evolving role of systemic therapy.
    Adsay NV; El-Rayes BF; Philip PA
    Expert Opin Pharmacother; 2001 Dec; 2(12):1939-47. PubMed ID: 11825326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.
    Van Laethem JL; Hammel P; Mornex F; Azria D; Van Tienhoven G; Vergauwe P; Peeters M; Polus M; Praet M; Mauer M; Collette L; Budach V; Lutz M; Van Cutsem E; Haustermans K
    J Clin Oncol; 2010 Oct; 28(29):4450-6. PubMed ID: 20837948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant therapy of pancreatic cancer: beyond gemcitabine. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
    Saif MW
    JOP; 2011 Mar; 12(2):106-9. PubMed ID: 21386631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.